ArticleJournal of addiction medicine
Clinician Perspectives on Barriers and Facilitators to Providing Medications for Opioid Use Disorder for Adolescents.
Article in Journal of addiction medicine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Review
- Statewide trends in access to medications for opioid use disorder (moud) among adolescents with opioid use disorders in Indiana.Drug and alcohol dependence reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectivesDespite rising adolescent opioid overdose deaths, adolescents under the age of 18 years are frequently excluded from the provision of medication for opioid use disorder (MOUD/OUD). As part of preimplementation work to inform the expansion of evidence-based practices to close this service gap, we designed this qualitative study to examine the perspectives of MOUD-providing clinicians on barriers and facilitators to providing MOUD for adolescents younger than 18.
methodsWe recruited clinicians who reported prescribing MOUD at least once per month, purposively sampling to include individuals who varied on training and practice backgrounds, experience prescribing to adolescents younger than 18, and practice settings (urban, suburban, and rural). We performed semistructured interviews and subsequent qualitative thematic analysis of transcripts.
resultsThree major barriers emerged: (1) the overcomplicated, intimidating nature of MOUD training and regulations, (2) poor understanding of MOUD treatment recommendations and consent/confidentiality laws for adolescents younger than 18, and (3) negative, stigmatizing views of adolescents with substance use disorders and the perceived difficulty of treating them. Facilitators identified included: (1) treatment demystification with adolescent-specific OUD implementation protocols/training, (2) clinician-to-clinician peer messaging and encouragement, and (3) formal family and community-level education medicalizing addiction.
conclusionsSignificant barriers to prescribing MOUD to adolescents younger than 18 persist despite the removal of federal training requirements. Comprehensive, multilevel adolescent-specific MOUD education paired with may expand the MOUD-prescribing workforce and improve treatment access. Further research should continue to explore these themes to inform policy and practice reforms aimed at improving outcomes for adolescents affected by OUD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.